Alpha-synuclein oligomers impair memory through glial cell activation and via Toll-like receptor 2.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Brain, behavior, and immunity

• Publication date

  2018-03-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.bbi.2018.02.012PMID 29458199
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Toll-like receptor 4-dependent glial cell activation mediates the impairment in memory establishment induced by β-amyloid oligomers in an acute mouse model of Alzheimer's disease.

  2017cited by this paper
• Combination therapies: The next logical Step for the treatment of synucleinopathies?

  2016cited by this paper
• Non-cell-autonomous Neurotoxicity of α-synuclein Through Microglial Toll-like Receptor 2

  2016cited by this paper
• Oligomeropathies and pathogenesis of Alzheimer and Parkinson's diseases

  2016cited by this paper
• Striatum and entorhinal cortex atrophy in AD mouse models: MRI comprehensive analysis.

  2015cited by this paper
• Toll-Like Receptor Expression in the Blood and Brain of Patients and a Mouse Model of Parkinson’s Disease

  2015cited by this paper
• Seeking a Mechanism for the Toxicity of Oligomeric α-Synuclein

  2015cited by this paper
• The relation between α-synuclein and microglia in Parkinson's disease: Recent developments.

  2015cited by this paper
• Intermittent fasting attenuates lipopolysaccharide-induced neuroinflammation and memory impairment

  2014cited by this paper
• Inflammatory response in Parkinson's disease (Review).

  2014cited by this paper
• Biological role of Toll-like receptor-4 in the brain.

  2014cited by this paper
• In vivo application of beta amyloid oligomers: a simple tool to evaluate mechanisms of action and new therapeutic approaches.

  2014cited by this paper
• Microglia as modulators of cognition and neuropsychiatric disorders

  2013cited by this paper
• One single method to produce native and Tat-fused recombinant human α-synuclein in Escherichia coli

  2013cited by this paper
• Microglia: a new frontier for synaptic plasticity, learning and memory, and neurodegenerative disease research.

  2013cited by this paper
• Direct Observation of the Interconversion of Normal and Toxic Forms of α-Synuclein

  2012cited by this paper
• α‐Synuclein oligomers oppose long‐term potentiation and impair memory through a calcineurin‐dependent mechanism: relevance to human synucleopathic diseases

  2012cited by this paper
• The Role of Glia in Alpha-Synucleinopathies

  2012cited by this paper
• Extracellular Alpha-Synuclein Oligomers Modulate Synaptic Transmission and Impair LTP Via NMDA-Receptor Activation

  2012cited by this paper
• Specific Recognition of Biologically Active Amyloid-β Oligomers by a New Surface Plasmon Resonance-based Immunoassay and an in Vivo Assay in Caenorhabditis elegans*

  2012cited by this paper
• In vivo demonstration that α-synuclein oligomers are toxic

  2011cited by this paper
• Glial dysfunction in the pathogenesis of α-synucleinopathies: emerging concepts

  2011cited by this paper
• Glia: Initiators and progressors of pathology in Parkinson's disease

  2011cited by this paper
• The effects of age on lipopolysaccharide-induced cognitive deficits and interleukin-1β expression.

  2011cited by this paper
• Alpha-synuclein release by neurons activates the inflammatory response in a microglial cell line.

  2011cited by this paper
• The acute inflammatory response to intranigral α-synuclein differs significantly from intranigral lipopolysaccharide and is exacerbated by peripheral inflammation

  2011cited by this paper
• Synthetic amyloid-β oligomers impair long-term memory independently of cellular prion protein

  2010cited by this paper
• Cognitive Deficits Associated with Alteration of Synaptic Metaplasticity Precede Plaque Deposition in AβPP23 Transgenic Mice

  2010cited by this paper
• Toll-like receptor 4 and high-mobility group box-1 are involved in ictogenesis and can be targeted to reduce seizures

  2010cited by this paper
• Screening of innate immune receptors in neurodegenerative diseases: a similar pattern.

  2009cited by this paper
• Cerebrospinal fluid a-synuclein in neurodegenerative disordersA marker of synapse loss?

  2009cited by this paper
• Mutant α-Synuclein Overexpression Mediates Early Proinflammatory Activity

  2009cited by this paper
• Systemic administration of lipopolysaccharide impairs glutathione redox state and object recognition in male mice. The effect of PARP-1 inhibitor.

  2009cited by this paper
• α-Synuclein activates stress signaling protein kinases in THP-1 cells and microglia

  2008cited by this paper
• Dementia in Parkinson's disease

  2008cited by this paper
• Neuroinflammation and Oxidation/Nitration of α-Synuclein Linked to Dopaminergic Neurodegeneration

  2008cited by this paper
• Synuclein activates microglia in a model of Parkinson's disease.

  2008cited by this paper
• Microglial activation mediates neurodegeneration related to oligodendroglial α‐synucleinopathy: Implications for multiple system atrophy

  2007cited by this paper
• Aggregated α‐synuclein activates microglia: a process leading to disease progression in Parkinson's disease

  2005cited by this paper
• A systematic review of prevalence and incidence studies of dementia with Lewy bodies.

  2005cited by this paper
• Dementia with Lewy bodies.

  2004cited by this paper
• DEMENTIA WITH LEWY BODIES

  2004cited by this paper
• α‐Synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma

  2003cited by this paper
• The role of alpha-synuclein in Parkinson's disease: insights from animal models.

  2003cited by this paper
• The role of α-synuclein in Parkinson's disease: insights from animal models

  2003cited by this paper
• Full length α-synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects

  2000cited by this paper
• Full length alpha-synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects.

  2000cited by this paper
• Activated microglia in dementia with Lewy bodies

  2000cited by this paper
• Inflammatory cytokines and related genes are induced in the rat hippocampus by limbic status epilepticus

  2000cited by this paper
• α‐Synuclein and Parkinson's disease: Selective neurodegenerative effect of α‐synuclein fragment on dopaminergic neurons in vitro and in vivo

  2000cited by this paper
• α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies

  1998cited by this paper
• alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies.

  1998cited by this paper
• Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies.

  1998cited by this paper
• Tumor necrosis factor-α (TNF-α) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients

  1994cited by this paper
• Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients.

  1994cited by this paper

• Perivascular spread of CSF-derived α-synuclein oligomers drives region-specific Parkinson's-like pathology.

  2026cites this paper
• Decreased neuronal and increased endothelial fractalkine expression are associated with neuroinflammation in Parkinson’s disease and related disorders

  2025cites this paper
• Structure based design, synthesis and identification of novel covalent reversible dual TLR2/TLR9 small molecule antagonists.

  2025cites this paper
• Adolescent mice exposed to TBI developed PD-like pathology in middle age

  2025cites this paper
• Regulatory mechanisms and therapeutic potential of natural microglia inhibitors in Parkinson's disease.

  2025cites this paper
• Ezetimibe mitigates microglial activation in Parkinson's disease via TLR4/JNK pathway inhibition: evidence from network pharmacology and experimental validation.

  2025cites this paper
• Retinal alterations resemble brain pathology in a rat model of Parkinson’s disease induced by intranigral infusion of α-synuclein oligomers

  2025cites this paper
• The role of autophagy in synucleinopathy: clearance versus spread of α-synuclein

  2025cites this paper
• Galectin-3 as a Key Driver of Neuroinflammation and α-Synuclein Aggregation in Parkinson's Disease: Unlocking New Paths for Biomarkers and Therapies.

  2025cites this paper
• The involvement of α-synucleinopathy in the disruption of microglial homeostasis contributes to the pathogenesis of Parkinson’s disease

  2024cites this paper
• α-Synuclein Oligomers in Skin Biopsies Predict the Worsening of Cognitive Functions in Parkinson’s Disease: A Single-Center Longitudinal Cohort Study

  2024cites this paper
• The Spreading and Effects of Human Recombinant α-Synuclein Preformed Fibrils in the Cerebrospinal Fluid of Mice

  2024cites this paper
• Cerebral Microvascular Injury Induced by Lag3‐Dependent α‐Synuclein Fibril Endocytosis Exacerbates Cognitive Impairment in a Mouse Model of α‐Synucleinopathies

  2023cites this paper
• Delivery of Biomimetic Liposomes via Meningeal Lymphatic Vessels Route for Targeted Therapy of Parkinson’s Disease

  2023cites this paper
• Alpha Synuclein: Neurodegeneration and Inflammation

  2023cites this paper
• The Interplay between α-Synuclein and Microglia in α-Synucleinopathies

  2023cites this paper
• Spreading of alpha-synuclein between different cell types.

  2022cites this paper
• Synaptic Disruption by Soluble Oligomers in Patients with Alzheimer’s and Parkinson’s Disease

  2022cites this paper
• Association of Cerebral Small Vessel Disease With Gait and Balance Disorders

  2022cites this paper
• Repositioning doxycycline for treating synucleinopathies: Evidence from a pre-clinical mouse model.

  2022cites this paper
• The role of Toll-like receptors and neuroinflammation in Parkinson’s disease

  2022cites this paper
• Task-specific effects of biological sex and sex hormones on object recognition memories in a 6-hydroxydopamine-lesion model of Parkinson’s disease in adult male and female rats

  2022cites this paper
• Does SARS-CoV-2 affect neurodegenerative disorders? TLR2, a potential receptor for SARS-CoV-2 in the CNS

  2022cites this paper
• RETRACTED ARTICLE: Aging exacerbates the brain inflammatory micro-environment contributing to α-synuclein pathology and functional deficits in a mouse model of DLB/PD

  2022cites this paper
• NPT1220-312, a TLR2/TLR9 Small Molecule Antagonist, Inhibits Pro-Inflammatory Signaling, Cytokine Release, and NLRP3 Inflammasome Activation

  2022cites this paper
• Extracellular alpha-synuclein: Sensors, receptors, and responses.

  2022cites this paper
• Neuroinflammation, immune response and α-synuclein pathology: how animal models are helping us to connect dots

  2022cites this paper
• Chronic Microcystin-LR-Induced α-Synuclein Promotes Neuroinflammation Through Activation of the NLRP3 Inflammasome in Microglia

  2022cites this paper
• Hypomyelinating Leukodystrophy 8 (HLD8)-Associated Mutation of POLR3B Leads to Defective Oligodendroglial Morphological Differentiation Whose Effect Is Reversed by Ibuprofen

  2022cites this paper
• Oligomeropathies, inflammation and prion protein binding

  2022cites this paper
• Mikroglial Toll-benzeri Reseptörlerin Alzheimer ve Parkinson Hastalıklarındaki Rolü

  2021cites this paper
• The Role of Toll-Like Receptor 4 in Infectious and Non Infectious Inflammation

  2021cites this paper
• Inflammation and Parkinson's disease pathogenesis: Mechanisms and therapeutic insight.

  2021cites this paper
• Contribution of astrocytes to neuropathology of neurodegenerative diseases.

  2021cites this paper
• Effects of innate immune receptor stimulation on extracellular α-synuclein uptake and degradation by brain resident cells

  2021cites this paper
• Extracellular α-Synuclein Modulates Iron Metabolism Related Proteins via Endoplasmic Reticulum Stress in MES23.5 Dopaminergic Cells

  2021cites this paper
• Reactive microglia enhance the transmission of exosomal alpha-synuclein via toll-like receptor 2.

  2021cites this paper
• Hippocampal Neurogenesis, Dopaminergic Neurons of the Substantia Nigra, and Behavior after Intranasal Administration of Native α-Synuclein Protein to Ageing Mice

  2021cites this paper
• Amyloid Prefibrillar Oligomers: The Surprising Commonalities in Their Structure and Activity

  2021cites this paper
• Phosphorylated α-synuclein aggregated in Schwann cells exacerbates peripheral neuroinflammation and nerve dysfunction in Parkinson’s disease through TLR2/NF-κB pathway

  2021cites this paper
• Experimental Models of Cognitive Impairment for Use in Parkinson’s Disease Research: The Distance Between Reality and Ideal

  2021cites this paper
• Repositioning doxycycline for treating Parkinson’s disease: Evidence from a pre‐clinical mouse model

  2021cites this paper
• Phosphorylated α-synuclein aggregated in Schwann cells exacerbates peripheral neuroinflammation and nerve dysfunction in Parkinson’s disease through TLR2/NF-κB pathway

  2021cites this paper
• Peripheral inflammation exacerbates α‐synuclein toxicity and neuropathology in Parkinson's models

  2020cites this paper
• MicroRNA-7, synergizes with RORα, negatively controls the pathology of brain tissue inflammation

  2020cites this paper
• TLR7/8 in the Pathogenesis of Parkinson’s Disease †

  2020cites this paper
• Alzheimer’s disease: from basic science to precision medicine approach

  2020cites this paper
• Parkinson’s disease: TLR2 ELEVATED AND DYSFUNCTION, POTENTIAL BENFIT FOR INHIBTION IN NEURONS, BUT MAY BE

  2020cites this paper
• TLR4 in Neurodegenerative Diseases: Alzheimer’s and Parkinson’s Diseases

  2020cites this paper
• Modeling Parkinson’s Disease Neuropathology and Symptoms by Intranigral Inoculation of Preformed Human α-Synuclein Oligomers

  2020cites this paper
• Postnatal Antioxidant and Anti-inflammatory Treatments Prevent Early Ketamine-Induced Cortical Dysfunctions in Adult Mice

  2020cites this paper
• Neuroinflammation and Alpha-Synuclein Oligomer Toxicity in the Pathogenesis of Lewy Body Dementia and Parkinson's Disease

  2020cites this paper
• Role of astroglial toll-like receptors (TLRs) in central nervous system infections, injury and neurodegenerative diseases

  2020cites this paper
• Metabolomics Fingerprint Induced by the Intranigral Inoculation of Exogenous Human Alpha-Synuclein Oligomers in a Rat Model of Parkinson’s Disease

  2020cites this paper
• The Potential Role of SARS-COV-2 in the Pathogenesis of Parkinson's Disease

  2020cites this paper
• Alpha-synuclein spreading pathology in Parkinson's disease: the influence of iron and the Rho-kinase inhibitor fasudil

  2020cites this paper
• Immune profiling of plasma-derived extracellular vesicles identifies Parkinson disease

  2020cites this paper
• Effect of chronic intranasal administration of α-synuclein oligomers on motor activity and anxiety in adult and middle-aged mice

  2019cites this paper
• Pα-syn* mitotoxicity is linked to MAPK activation and involves tau phosphorylation and aggregation at the mitochondria.

  2019cites this paper
• Pharmacological Targeting of Microglial Activation: New Therapeutic Approach

  2019cites this paper
• Targeting Microglial and Neuronal Toll-like Receptor 2 in Synucleinopathies

  2019cites this paper
• Biophysical and in vivo studies identify a new natural-based polyphenol, counteracting Aβ oligomerization in vitro and Aβ oligomer-mediated memory impairment and neuroinflammation in an acute mouse model of Alzheimer's disease.

  2019cites this paper
• Toll-like receptors and their therapeutic potential in Parkinson's disease and α-synucleinopathies.

  2019cites this paper
• Interferon-γ Potentiates α-Synuclein-induced Neurotoxicity Linked to Toll-like Receptors 2 and 3 and Tumor Necrosis Factor-α in Murine Astrocytes

  2019cites this paper
• Hapln2 in Neurological Diseases and Its Potential as Therapeutic Target

  2019cites this paper
• Review: PrP 106‐126 – 25 years after

  2019cites this paper
• Cellular prion protein neither binds to alpha-synuclein oligomers nor mediates their detrimental effects

  2019cites this paper
• Oligomers: a hot topic for neurodegeneration and a note of caution for experimental models.

  2019cites this paper
• Lewy Body Dementia and the Role of Inflammation

  2018cites this paper
• Sensing α‐Synuclein From the Outside via the Prion Protein: Implications for Neurodegeneration

  2018cites this paper